CCIA
ATNM icon

Campbell & Co Investment Adviser’s Actinium Pharmaceuticals ATNM Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-32,034
Closed -$237K – 1081
2024
Q2 		$237K Buy
+32,034
New +$264K 0.02% 910

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Campbell & Co Investment Adviser's ATNM Position: Q3 2024 in Review

Campbell & Co Investment Adviser sold out of Actinium Pharmaceuticals (ATNM) in Q3 2024, closing a stake of 32,034 shares — an estimated $237K sold.

Campbell & Co Investment Adviser first reported a position in ATNM in Q2 2024 and held it in 1 quarter. The position peaked at $237K in Q2 2024. 72 funds tracked by Wall St. Rank hold ATNM as of Q3 2024.

  • Campbell & Co Investment Adviser reported no remaining Actinium Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 32,034 Actinium Pharmaceuticals shares in Q3 2024, an estimated $237K.
  • Campbell & Co Investment Adviser first reported a position in Actinium Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Actinium Pharmaceuticals position peaked at $237K in Q2 2024.
  • 72 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2024, filed 12 Nov 2024.